Opsona Appoints Dr Martin Welschof as CEO and Conor Dalton as Director of Finance
2012-02-09
February 9th, 2012, Dublin, Ireland - Opsona Therapeutics, the innate immune drug development company, today announced that it has appointed two experienced biopharm executives to complement its management team.
Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
2011-07-05
- Commenting on this announcement; Bernd R. Seizinger, M.D., Ph.D., Executive Chairman of Opsona Therapeutics said," OPN-305 is a first-in-class antibody against Toll-like- Receptor 2, one of the most promising novel drug targets in the innate immune system. TLR-2 has been linked to an increasing number of major human diseases, including autoimmune diseases, renal ischemia, myocardial infarction, stroke and cancer. This phase 1 study will provide the basis to explore the broad medical and commercial viability and opportunity of OPN- 305 in a variety of indications with unmet medical needs."
Martin Welschof, Opsona:"Inventages had the vision and courage to support Opsona's quest to develop first in class and revolutionary treatment option targeting key structures of the innate immune system."
